Vascular Diseases Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Vascular Diseases. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Vascular Diseases receives a directional strategic score of 56/100, combining unmet need (54/100), competitive intensity (96/100, where higher means more competition) and market attractiveness (95/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.

The reproducible entity is Patsnap disease ID 37aac2c87e904ab3bdeda47ef4faf2a5 with MeSH identifier D014652. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Mortality Due to COVID-19 in Different Countries is Associated with their Demographic Character and Prevalence of Autoimmunity Mortality due to COVID-19 in different countries is associated with their demographic character and prevalence of autoimmunity

1. GBD 2017 Disease and Injury Incidence and Prevalence Collabo- rators, Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392, 1789– 1858. 2. Pan, H.-Y. et al., National incidence of autoimmune liver diseases and its relationship with the human development index. Oncotar- get, 2016, 7, 46273–46282. 3. https://datahelpdesk-worldbank-org.sutd.idm.oclc.org/knowledgebase/articles/90651- 9-world-bank-country-and-lending-groups (accessed on 29 June 2020). 4. Li, B. et al., Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol., 2020, 109, 531–538. 5. Yang, J. et al., Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta- analysis. Int. J. Infect. Dis., 2020, 94, 91–95. 6. Emami, A., Javanmardi, F., Pirbonyeh, N. and Akbari, A., Preva- lence of underlying diseases in hospitalized patients with COVID- 19: a systematic review and meta-analysis. Arch. Acad. Emerg. Med., 2020, 8(1), e35. 7. UN, COVID-19 and older persons: a defining moment for an informed, inclusive and targeted response. United Nations for Ageing; https://www.un.org/development/desa/ageing/news/2020/ 05/covid19/ (accessed on 29 June 2020). 8. Roser, M., Human development index (HDI). Our World in Data, 2014; https://ourworldindata.org/human-developmentindex#:~:text= The%20Human%20Development%20Index%20(HDI)%20provides %20a%20single%20index%20me

Review the epidemiology source

Epidemiology evidence 2: Trends and Demographics of Vascular Intestinal Diseases-Related Mortality Among Adults Living in United States From 1999 to 2020; A CDC Wonder Analysis Trends and Demographics of Vascular Intestinal Diseases-­Related Mortality Among Adults Living in United States From 1999 to 2020; A CDC Wonder Analysis

in Winter,” International Journal of Colorectal Disease 34, no. 12 (2019): 2059–2067. 4. G. Lippi, C. Mattiuzzi, and F. Sanchis-­Gomar, “Large-­Scale Epide- miological Data on Vascular Disorders of the Intestine,” Scandinavian Journal of Gastroenterology 55, no. 5 (2020): 621–625. 5. M. J. Madurska, R. G. Anderson, D. J. Anderson, et al., “Mesenteric Vascular Disease: A Population-­Based Cohort Study,” Vascular 29, no. 1 (2021): 54–60. 6. P. Danpanichkul, Y. Kanjanakot, S. Kongarin, et al., “The Growing Trend of Vascular Intestinal Disorder in Young Individuals: A 20-­Year Analysis,” Annals of Gastroenterology 37, no. 4 (2024): 458–465. 7. V. R. Katikala, M. Gm, B. Koyani, et al., “S996 Cross-­State Compar- ative Assessment of Burden of Vascular Intestinal Disorders and Its Trend in the United States From 1990-­2021: A Benchmarking Second- ary Analysis From the Global Burden of Disease Study 2021,” American Journal of Gastroenterology 119, no. 10S (2024): S698–S699. 8. Centers for Disease Control and Prevention, CDC Wonder (Cdc.gov, 2021), https://​wonder.​cdc.​gov/​. 9. ICD10Data.com, ICD-­10-­CM Codes (Icd10data.com, 2019), https://​ www.​icd10​data.​com/​ICD10​CM/​Codes​. 10. E. von Elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. Gøtzsche, and J. P. Vandenbroucke, “The Strengthening the Reporting of Obser- vational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies,” Journal of Clinical Epidemiology 61, no. 4 (2008): 344–349, https://​doi.​org/​10.​1016/j.​jclin​epi.​2007.​11.​008. 11. Joinpoint Regression Program, surveillance.ca

Review the epidemiology source

Epidemiology evidence 3: Prevalence of vasculitis, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies and spondyloarthritis in Australia : a systematic review and meta‐analysis Prevalence of vasculitis, systemic lupus erythematosus,rheumatoid arthritis, systemic sclerosis, idiopathic inflammatorymyopathies and spondyloarthritis in Australia: a systematicreview and meta-analysis

This is the first systematic review and meta-analysis of vas- culitis, SLE, RA, SSc, IIM, SpA, SjD and MCTD incidence or prevalence in Australia, highlighting the challenges of generating high-quality data for rare diseases with nuanced diagnostic criteria. Three research gaps were identified. First, prevalence/incidence data are limited for non-ANCA-associated vasculitis, SpA, RA, SLE in SA, MCTD and SjD. In those SARDs with existing prevalence/ incidence estimates, there remains a paucity of data from some population groups, with limited studies in the paedi- atric population and Australians of Asian descent. Second, validation studies could strengthen the use of Australian administrative health data for SARD research. Finally, geo- graphic variation in AAV, SLE and SSc prevalence may be considerable but requires further investigation.

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Vascular Diseases, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Vascular Diseases thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: COL1A1

Type I collagen is a member of group I collagen (fibrillar forming collagen).

The mechanism anchor is COL1A1. It is a pathway hypothesis, not a claim that every Vascular Diseases patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 87688 registered studies. Recent sampled records include:

• JPRN-UMIN000062033 — Meteorological and Environmental Factors Associated with the Onset of Subarachnoid Hemorrhage; 開始前/Preinitiation; Not Applicable; sponsor University of Tokushima; enrollment 200.
• ChiCTR2600130710 — Research on the Mechanism of Ovarian Aging; Not yet recruiting; Not Applicable; sponsor The Second Affiliated Hospital of Chongqing Medical University; enrollment 50.
• ChiCTR2600130695 — Clinical Research on the Efficacy of All G Lactoferrin for Skin Anti-allergy, Repairing and Soothing, Skin Barrier Improvement, and Skin Microbiota Balance Modulation; Completed; Not Applicable; sponsor Shanghai Fengxian District Central Hospital; enrollment 33.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

The search returned 42 recent directly matched transaction records:

• Hanmi Pharm signs contract with Viet Phap to supply hypertension combo drugs (2025-11-05). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.
• Kiniksa exercised its right to terminate its exclusive license agreement for mavrilimumab with MedImmune. (2025-02-25). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.
• George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America (2025-01-13). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate COL1A1 relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Vascular Diseases merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if COL1A1 modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Vascular Diseases is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.